Subunit-selective NMDA Receptor Modulators (SNRMs)
Learning and memory dysfunction is a major unmet medical need in neuropsychiatry and cognitive disorders encompass a significant portion of the broader $80B mental health market. The NMDA receptor is widely recognized as the ‘master switch’ for learning and memory, and a large body of preclinical and clinical research supports targeting this receptor to treat a broad range of neuropsychiatric disorders. Mnemosyne is developing a new class of drugs, the Subunit-selective NMDA Receptor Modulators (SNRMs), to address this area of need.
Mnemosyne’s lead program is for schizophrenia, and the company is exploring additional indications including Alzheimer’s disease, recovery from stroke and traumatic brain injury, and attention deficit/hyperactivity disorder (ADHD).
Mnemosyne is the Greek goddess of memory. In this mosaic from the 3rd century B.C., the goddess aids memory by the touch of her hand.